Bioanalysis Zone

Quantification of serum purine metabolites for distinguishing patients with hepatitis B from hepatocellular carcinoma


Aim: In order to differential diagnosis of chronic hepatitis B (HBV-I) and hepatocellular carcinoma (HCC), a UPLC–MS/MS method for measuring purine metabolites was developed.

Hepatocellular carcinoma (HCC) is a disease that seriously threatens human health. It is the fourth most common and third most malignant tumor in the world [1]. The occurrence of HCC is closely related to hepatitis virus infection. There are more than 200 million chronic hepatitis B (HBV-I)-infected individuals in the world. HCC often has high mortality rate, and its 5-year survival rate is only 10% [2–5]. China is a country with high incidence of hepatitis virus infection. There are about 320,000 cases of death caused by HCC every year, accounting for 51% of the death cases of HCC worldwide, far higher than the world average [1]. Given the tendency of early metastasis and invasion into other tissues, the prevention and treatment of HCC is a worldwide medical problem, and there is still a lack of effective means to prevent and cure it. Therefore, the early diagnosis of HCC has become the focus of scientists in the medical and life science field [6,7].

Metabolism is a continuous and complex process. Metabonomics is a powerful tool used for the investigation of metabolic processes in vivo [8]. In recent years, studies using metabonomics technology have obtained valuable research findings for HCC diagnosis [9–11].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment